Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

Journal of Experimental Medicine

Volumn 212, Issue 12, 2015, Pages 2095-2113

  Palmer, Douglas C ^a   Guittard, Geoffrey C ^a   Franco, Zulmarie ^a   Crompton, Joseph G ^a   Eil, Robert L ^a   Patel, Shashank J ^a   Ji, Yun ^a   Van Panhuys, Nicholas ^b   Klebanoff, Christopher A ^a   Sukumar, Madhusudhanan ^a   Clever, David ^a,c   Chichura, Anna ^a   Roychoudhuri, Rahul ^a   Varma, Rajat ^b   Wang, Ena ^d   Gattinoni, Luca ^a   Marincola, Francesco M ^d   Balagopalan, Lakshmi ^a   Samelson, Lawrence E ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CISH PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANZYME; INHIBITOR OF DIFFERENTIATION 3; INTERLEUKIN 2; LAT PROTEIN; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN KINASE ZAP 70; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE INDUCIBLE SH2-CONTAINING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PHOSPHOLIPASE C GAMMA; PROTEIN BINDING; TRANSCRIPTOME;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE DELETION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UPREGULATION; 129 MOUSE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; DEFICIENCY; DNA MICROARRAY; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNE TOLERANCE; IMMUNOBLOTTING; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOLIPASE C GAMMA; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84948654905     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20150304     Document Type: Article

References (87)

1. Acquavella, N., D. Clever, Z. Yu, M. Roelke-Parker, D.C. Palmer, L. Xi, H. Pflicke, Y. Ji, A. Gros, K. Hanada, et al. 2015. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol. Res. 3: 37-47. http://dx.doi.org/10.1158/2326 -6066.CIR -14 -0122
2. Acuto, O., V. Di Bartolo, and F. Michel. 2008. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat. Rev. Immunol. 8: 699-712. http://dx.doi.org/10.1038/nri2397
3. Aman, M.J., T.-S. Migone, A. Sasaki, D.P. Ascherman, Mh. Zhu, E. Soldaini, K. Imada, A. Miyajima, A. Yoshimura, and W.J. Leonard. 1999. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J. Biol. Chem. 274: 30266-30272. http://dx.doi.org/10.1074/jbc.274.42.30266
4. Antony, P.A., C.A. Piccirillo, A. Akpinarli, S.E. Finkelstein, P.J. Speiss, D.R. Surman, D.C. Palmer, C.-C. Chan, C.A. Klebanoff, W.W. Overwijk, et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601. http://dx.doi.org/10.4049/jimmunol.174.5.2591
5. Arens, R., and S.P. Schoenberger. 2010. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol. Rev. 235: 190-205.
6. Babon, J.J., E.J. McManus, S. Yao, D.P. DeSouza, L.A. Mielke, N.S. Sprigg, T.A. Willson, D.J. Hilton, N.A. Nicola, M. Baca, et al. 2006. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol. Cell. 22: 205-216. http://dx.doi.org/10.1016/j.molcel.2006.03.024
7. Balagopalan, L., B.A. Ashwell, K.M. Bernot, I.O. Akpan, N. Quasba, V.A. Barr, and L.E. Samelson. 2011. Enhanced T-cell signaling in cells bearing linker for activation of T-cell (LAT) molecules resistant to ubiquitylation. Proc. Natl. Acad. Sci. USA. 108: 2885-2890. http://dx.doi.org/10.1073/pnas.1007098108
8. Batista, F.D., and M.L. Dustin. 2013. Cell:cell interactions in the immune system. Immunol. Rev. 251: 7-12. http://dx.doi.org/10.1111/imr.12025
9. Berg, L.J., L.D. Finkelstein, J.A. Lucas, and P.L. Schwartzberg. 2005. Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol. 23: 549-600. http://dx.doi.org/10.1146/annurev.immunol.22.012703.104743
10. Best, J.A., D.A. Blair, J. Knell, E. Yang, V. Mayya, A. Doedens, M.L. Dustin, and A.W. Goldrath. Immunological Genome Project Consortium. 2013. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat. Immunol. 14: 404-412. http://dx.doi.org/10.1038/ni.2536
11. Braiman, A., M. Barda-Saad, C.L. Sommers, and L.E. Samelson. 2006. Recruitment and activation of PLCgamma1 in T cells: a new insight into old domains. EMBO J. 25: 774-784. http://dx.doi.org/10.1038/sj.emboj.7600978
12. Bunnell, S.C., D.I. Hong, J.R. Kardon, T. Yamazaki, C.J. McGlade, V.A. Barr, and L.E. Samelson. 2002. T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. 158: 1263-1275. http://dx.doi.org/10.1083/jcb.200203043
13. Catlett, I.M., and S.M. Hedrick. 2005. Suppressor of cytokine signaling 1 is required for the differentiation of CD4+ T cells. Nat. Immunol. 6: 715-721. http://dx.doi.org/10.1038/ni1211
14. Chaigne-Delalande, B., F.Y. Li, G.M. O'Connor, M.J. Lukacs, P. Jiang, L. Zheng, A. Shatzer, M. Biancalana, S. Pittaluga, H.F. Matthews, et al. 2013. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 341: 186-191. http://dx.doi.org/10.1126/science.1240094
15. Chervin, A.S., J.D. Stone, C.M. Soto, B. Engels, H. Schreiber, E.J. Roy, and D.M. Kranz. 2013. Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther. 20: 634-644. http://dx.doi.org/10.1038/gt.2012.80
16. Cohney, S.J., D. Sanden, N.A. Cacalano, A. Yoshimura, A. Mui, T.S. Migone, and J.A. Johnston. 1999. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell. Biol. 19: 4980-4988.
17. Davey, G.M., R. Starr, A.L. Cornish, J.T. Burghardt, W.S. Alexander, F.R. Carbone, C.D. Surh, and W.R. Heath. 2005. SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential. J. Exp. Med. 202: 1099-1108. http://dx.doi.org/10.1084/jem.20050003
18. Davis, J.L., M.R. Theoret, Z. Zheng, C.H.J. Lamers, S.A. Rosenberg, and R.A. Morgan. 2010. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16: 5852-5861. http://dx.doi.org/10.1158/1078 -0432.CCR -10 -1280
19. Dif, F., E. Saunier, B. Demeneix, P.A. Kelly, and M. Edery. 2001. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor. Endocrinology. 142: 5286-5293. http://dx.doi.org/10.1210/endo.142.12.8549
20. Dissanayake, D., M.A. Gronski, A. Lin, A.R. Elford, and P.S. Ohashi. 2011. Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. Immunol. Rev. 241: 164-179. http://dx.doi.org/10.1111/j.1600 -065X.2011.01014.x
21. Dranoff, G. 2013. Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. Nat. Med. 19: 1100-1101. http://dx.doi.org/10.1038/nm.3335
22. Dranoff, G., and D. Fearon. 2013. Tumour immunology. Curr. Opin. Immunol. 25: 189-191. http://dx.doi.org/10.1016/j.coi.2013.02.012
23. Dudda, J.C., B. Salaun, Y. Ji, D.C. Palmer, G.C. Monnot, E. Merck, C. Boudousquie, D.T. Utzschneider, T.M. Escobar, R. Perret, et al. 2013. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 38: 742-753. http://dx.doi.org/10.1016/j.immuni.2012.12.006
24. Endo, T., A. Sasaki, M. Minoguchi, A. Joo, and A. Yoshimura. 2003. CIS1 interacts with the Y532 of the prolactin receptor and suppresses prolactin-dependent STAT5 activation. J. Biochem. 133: 109-113. http://dx.doi.org/10.1093/jb/mvg004
25. Endo, T.A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387: 921-924. http://dx.doi.org/10.1038/43213
26. Gajewski, T.F., H. Schreiber, and Y.-X. Fu. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14: 1014-1022. http://dx.doi.org/10.1038/ni.2703
27. Goldrath, A.W., C.J. Luckey, R. Park, C. Benoist, and D. Mathis. 2004. The molecular program induced in T cells undergoing homeostatic proliferation. Proc. Natl. Acad. Sci. USA. 101: 16885-16890. http://dx.doi.org/10.1073/pnas.0407417101
28. Gronski, M.A., J.M. Boulter, D. Moskophidis, L.T. Nguyen, K. Holmberg, A.R. Elford, E.K. Deenick, H.O. Kim, J.M. Penninger, B. Odermatt, et al. 2004. TCR affinity and negative regulation limit autoimmunity. Nat. Med. 10: 1234-1239. http://dx.doi.org/10.1038/nm1114
29. Guittard, G., R.L. Kortum, L. Balagopalan, N. Çuburu, P. Nguyen, C.L. Sommers, and L.E. Samelson. 2015. Absence of both Sos-1 and Sos-2 in peripheral CD4+ T cells leads to PI3K pathway activation and defects in migration. Eur. J. Immunol. 45: 2389-2395. http://dx.doi.org/10.1002/eji.201445226
30. Harlin, H., T.V. Kuna, A.C. Peterson, Y. Meng, and T.F. Gajewski. 2006. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55: 1185-1197. http://dx.doi.org/10.1007/s00262 -005 -0118 -2
31. Hilton, D.J., R.T. Richardson, W.S. Alexander, E.M. Viney, T.A. Willson, N.S. Sprigg, R. Starr, S.E. Nicholson, D. Metcalf, and N.A. Nicola. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA. 95: 114-119. http://dx.doi.org/10.1073/pnas.95.1.114
32. Hodi, F.S., and G. Dranoff. 2010. The biologic importance of tumor-infiltrating lymphocytes. J. Cutan. Pathol. 37: 48-53. http://dx.doi.org/10.1111/j.1600 -0560.2010.01506.x
33. Janicki, C.N., S.R. Jenkinson, N.A. Williams, and D.J. Morgan. 2008. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res. 68: 2993-3000. http://dx.doi.org/10.1158/0008 -5472.CAN -07 -5008
34. Ji, Y., Z. Pos, M. Rao, C.A. Klebanoff, Z. Yu, M. Sukumar, R.N. Reger, D.C. Palmer, Z.A. Borman, P. Muranski, et al. 2011. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat. Immunol. 12: 1230-1237. http://dx.doi.org/10.1038/ni.2153
35. Jin, P., E. Wang, M. Provenzano, S. Deola, S. Selleri, J. Ren, S. Voiculescu, D. Stroncek, M.C. Panelli, and F.M. Marincola. 2006. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J. Transl. Med. 4: 26. http://dx.doi.org/10.1186/1479 -5876 -4 -26
36. Johnson, L.A., B. Heemskerk, D.J. Powell Jr., C.J. Cohen, R.A. Morgan, M.E. Dudley, P.F. Robbins, and S.A. Rosenberg. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177: 6548-6559. http://dx.doi.org/10.4049/jimmunol.177.9.6548
37. June, C.H., M.C. Fletcher, J.A. Ledbetter, G.L. Schieven, J.N. Siegel, A.F. Phillips, and L.E. Samelson. 1990. Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 87: 7722-7726. http://dx.doi.org/10.1073/pnas.87.19.7722
38. Kaech, S.M., S. Hemby, E. Kersh, and R. Ahmed. 2002a. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 111: 837-851. http://dx.doi.org/10.1016/S0092 -8674(02)01139 -X
39. Kaech, S.M., E.J. Wherry, and R. Ahmed. 2002b. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2: 251-262. http://dx.doi.org/10.1038/nri778
40. Kalos, M., and C.H. June. 2013. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 39: 49-60. http://dx.doi.org/10.1016/j.immuni.2013.07.002
41. Kamizono, S., T. Hanada, H. Yasukawa, S. Minoguchi, R. Kato, M. Minoguchi, K. Hattori, S. Hatakeyama, M. Yada, S. Morita, et al. 2001. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276: 12530-12538. http://dx.doi.org/10.1074/jbc.M010074200
42. Kerkar, S.P., P. Muranski, A. Kaiser, A. Boni, L. Sanchez-Perez, Z. Yu, D.C. Palmer, R.N. Reger, Z.A. Borman, L. Zhang, et al. 2010. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70: 6725-6734. http://dx.doi.org/10.1158/0008 -5472.CAN -10 -0735
43. Khor, C.C., F.O. Vannberg, S.J. Chapman, H. Guo, S.H. Wong, A.J. Walley, D. Vukcevic, A. Rautanen, T.C. Mills, K.C. Chang, et al. 2010. CISH and susceptibility to infectious diseases. N. Engl. J. Med. 362: 2092-2101. http://dx.doi.org/10.1056/NEJMoa0905606
44. King, C.G., S. Koehli, B. Hausmann, M. Schmaler, D. Zehn, and E. Palmer. 2012. T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology. Immunity. 37: 709-720. http://dx.doi.org/10.1016/j.immuni.2012.06.021
45. Landsman, T., and D.J. Waxman. 2005. Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization. J. Biol. Chem. 280: 37471-37480. http://dx.doi.org/10.1074/jbc.M504125200
46. Li, S., S. Chen, X. Xu, A. Sundstedt, K.M. Paulsson, P. Anderson, S. Karlsson, H.O. Sjögren, and P. Wang. 2000. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J. Exp. Med. 191: 985-994. http://dx.doi.org/10.1084/jem.191.6.985
47. Linette, G.P., E.A. Stadtmauer, M.V. Maus, A.P. Rapoport, B.L. Levine, L. Emery, L. Litzky, A. Bagg, B.M. Carreno, P.J. Cimino, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 122: 863-871. http://dx.doi.org/10.1182/blood -2013 -03 -490565
48. Malecek, K., S. Zhong, K. McGary, C. Yu, K. Huang, L.A. Johnson, S.A. Rosenberg, and M. Krogsgaard. 2013. Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J. Immunol. Methods. 392: 1-11. http://dx.doi.org/10.1016/j.jim.2013.02.018
49. Manicassamy, S., S. Gupta, Z. Huang, and Z. Sun. 2006. Protein kinase C-theta-mediated signals enhance CD4+ T cell survival by up-regulating Bcl-xL. J. Immunol. 176: 6709-6716. http://dx.doi.org/10.4049/jimmunol.176.11.6709
50. Matsumoto, A., M. Masuhara, K. Mitsui, M. Yokouchi, M. Ohtsubo, H. Misawa, A. Miyajima, and A. Yoshimura. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 89: 3148-3154.
51. Maus, M.V., J.A. Fraietta, B.L. Levine, M. Kalos, Y. Zhao, and C.H. June. 2014. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32: 189-225. http://dx.doi.org/10.1146/annurev -immunol -032713 -120136
52. Morgan, R.A., N. Chinnasamy, D. Abate-Daga, A. Gros, P.F. Robbins, Z. Zheng, M.E. Dudley, S.A. Feldman, J.C. Yang, R.M. Sherry, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36: 133-151. http://dx.doi.org/10.1097/CJI.0b013e3182829903
53. Mortarini, R., A. Piris, A. Maurichi, A. Molla, I. Bersani, A. Bono, C. Bartoli, M. Santinami, C. Lombardo, F. Ravagnani, et al. 2003. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63: 2535-2545.
54. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387: 924-929. http://dx.doi.org/10.1038/43219
55. Nauerth, M., B. Weißbrich, R. Knall, T. Franz, G. Dössinger, J. Bet, P.J. Paszkiewicz, L. Pfeifer, M. Bunse, W. Uckert, et al. 2013. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci. Transl. Med. 5:192ra87.
56. Ohashi, P.S., S. Oehen, K. Buerki, H. Pircher, C.T. Ohashi, B. Odermatt, B. Malissen, R.M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 65: 305-317.
57. Overwijk, W.W., M.R. Theoret, S.E. Finkelstein, D.R. Surman, L.A. de Jong, F.A. Vyth-Dreese, T.A. Dellemijn, P.A. Antony, P.J. Spiess, D.C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580. http://dx.doi.org/10.1084/jem.20030590
58. Palmer, D.C., and N.P. Restifo. 2009. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 30: 592-602. http://dx.doi.org/10.1016/j.it.2009.09.009
59. Palmer, D.C., C.C. Chan, L. Gattinoni, C. Wrzesinski, C.M. Paulos, C.S. Hinrichs, D.J. Powell Jr., C.A. Klebanoff, S.E. Finkelstein, R.N. Fariss, et al. 2008. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. USA. 105: 8061-8066. http://dx.doi.org/10.1073/pnas.0710929105
60. Rabinovich, G.A., D. Gabrilovich, and E.M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296. http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609
61. Rao, M., N. Chinnasamy, J.A. Hong, Y. Zhang, M. Zhang, S. Xi, F. Liu, V.E. Marquez, R.A. Morgan, and D.S. Schrump. 2011. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 71: 4192-4204. http://dx.doi.org/10.1158/0008 -5472.CAN -10 -2442
62. Restifo, N.P., M.E. Dudley, and S.A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281. http://dx.doi.org/10.1038/nri3191
63. Rosati, S.F., M.R. Parkhurst, Y. Hong, Z. Zheng, S.A. Feldman, M. Rao, D. Abate-Daga, R.E. Beard, H. Xu, M.A. Black, et al. 2014. A novel murine T-cell receptor targeting NY-ESO-1. J. Immunother. 37: 135-146. http://dx.doi.org/10.1097/CJI.0000000000000019
64. Rosenberg, S.A., R.M. Sherry, K.E. Morton, W.J. Scharfman, J.C. Yang, S.L. Topalian, R.E. Royal, U. Kammula, N.P. Restifo, M.S. Hughes, et al. 2005. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175: 6169-6176. http://dx.doi.org/10.4049/jimmunol.175.9.6169
65. Scholer, A., S. Hugues, A. Boissonnas, L. Fetler, and S. Amigorena. 2008. Intercellular adhesion molecule-1-dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity. 28: 258-270. http://dx.doi.org/10.1016/j.immuni.2007.12.016
66. Seki, Y., H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, K. Matsumoto, O. Komine, S. Hamano, K. Himeno, K. Inagaki-Ohara, et al. 2003. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat. Med. 9: 1047-1054. http://dx.doi.org/10.1038/nm896
67. Smith-Garvin, J.E., G.A. Koretzky, and M.S. Jordan. 2009. T cell activation. Annu. Rev. Immunol. 27: 591-619. http://dx.doi.org/10.1146/annurev.immunol.021908.132706
68. Sommers, C.L., J. Lee, K.L. Steiner, J.M. Gurson, C.L. Depersis, D. El-Khoury, C.L. Fuller, E.W. Shores, P.E. Love, and L.E. Samelson. 2005. Mutation of the phospholipase C-gamma1-binding site of LAT affects both positive and negative thymocyte selection. J. Exp. Med. 201: 1125-1134. http://dx.doi.org/10.1084/jem.20041869
69. Starr, R., T.A. Willson, E.M. Viney, L.J. Murray, J.R. Rayner, B.J. Jenkins, T.J. Gonda, W.S. Alexander, D. Metcalf, N.A. Nicola, and D.J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature. 387:917-921. http://dx.doi.org/10.1038/43206
70. Taleb, S., M. Romain, B. Ramkhelawon, C. Uyttenhove, G. Pasterkamp, O. Herbin, B. Esposito, N. Perez, H. Yasukawa, J. Van Snick, et al. 2009. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 206: 2067-2077. http://dx.doi.org/10.1084/jem.20090545
71. Tanaka, K., K. Ichiyama, M. Hashimoto, H. Yoshida, T. Takimoto, G. Takaesu, T. Torisu, T. Hanada, H. Yasukawa, S. Fukuyama, et al. 2008. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J. Immunol. 180: 3746-3756. http://dx.doi.org/10.4049/jimmunol.180.6.3746
72. Thaventhiran, J.E., D.T. Fearon, and L. Gattinoni. 2013. Transcriptional regulation of effector and memory CD8+ T cell fates. Curr. Opin. Immunol. 25: 321-328. http://dx.doi.org/10.1016/j.coi.2013.05.010
73. Tong, H.V., N.L. Toan, H. Song, P.G. Kremsner, J.F. Kun, and V. Tp. 2012. Association of CISH -292A/T genetic variant with hepatitis B virus infection. Immunogenetics. 64: 261-265. http://dx.doi.org/10.1007/s00251 -011 -0584 -y
74. Uyttendaele, I., I. Lemmens, A. Verhee, A.S. De Smet, J. Vandekerckhove, D. Lavens, F. Peelman, and J. Tavernier. 2007. Mammalian protein-protein interaction trap (MAP PIT) analysis of STAT5, CIS, and SOCS2 interactions with the growth hormone receptor. Mol. Endocrinol. 21: 2821-2831. http://dx.doi.org/10.1210/me.2006 -0541
75. Vazquez-Cintron, E.J., N.R. Monu, and A.B. Frey. 2010. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J. Immunol. 185: 7133-7140. http://dx.doi.org/10.4049/jimmunol.1001157
76. Whiteside, T.L. 2006. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16: 3-15. http://dx.doi.org/10.1016/j.semcancer.2005.07.008
77. Yang, X.O., H. Zhang, B.S. Kim, X. Niu, J. Peng, Y. Chen, R. Kerketta, Y.H. Lee, S.H. Chang, D.B. Corry, et al. 2013. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat. Immunol. 14: 732-740. http://dx.doi.org/10.1038/ni.2633
78. Yasukawa, H., A. Sasaki, and A. Yoshimura. 2000. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18: 143-164. http://dx.doi.org/10.1146/annurev.immunol.18.1.143
79. Yokosuka, T., K. Sakata-Sogawa, W. Kobayashi, M. Hiroshima, A. Hashimoto-Tane, M. Tokunaga, M.L. Dustin, and T. Saito. 2005. Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nat. Immunol. 6: 1253-1262. http://dx.doi.org/10.1038/ni1272
80. Yoshimura, A. 2013. CIS: the late-blooming eldest son. Nat. Immunol. 14: 692-694. http://dx.doi.org/10.1038/ni.2645
81. Yoshimura, A., T. Ohkubo, T. Kiguchi, N.A. Jenkins, D.J. Gilbert, N.G. Copeland, T. Hara, and A. Miyajima. 1995. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14: 2816-2826.
82. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7: 454-465. http://dx.doi.org/10.1038/nri2093
83. Zhang, N., and M.J. Bevan. 2011. CD8+ T cells: foot soldiers of the immune system. Immunity. 35: 161-168. http://dx.doi.org/10.1016/j.immuni.2011.07.010
84. Zhang, J.G., A. Farley, S.E. Nicholson, T.A. Willson, L.M. Zugaro, R.J. Simpson, R.L. Moritz, D. Cary, R. Richardson, G. Hausmann, et al. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA. 96: 2071-2076. http://dx.doi.org/10.1073/pnas.96.5.2071
85. Zhang, L., S.A. Feldman, Z. Zheng, N. Chinnasamy, H. Xu, A.V. Nahvi, M.E. Dudley, S.A. Rosenberg, and R.A. Morgan. 2012. Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J. Immunother. 35: 430-439. http://dx.doi.org/10.1097/CJI.0b013e31825898e8
86. Zhao, Y., A.D. Bennett, Z. Zheng, Q.J. Wang, P.F. Robbins, L.Y.L. Yu, Y. Li, P.E. Molloy, S.M. Dunn, B.K. Jakobsen, et al. 2007. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179: 5845-5854. http://dx.doi.org/10.4049/jimmunol.179.9.5845
87. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Liénard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64: 2865-2873. http://dx.doi.org/10.1158/0008 -5472.CAN -03 -3066